DHR Danaher Corporation

Price (delayed)

$182.04

Market cap

$127.64B

P/E Ratio

40.94

Dividend/share

$0.7

EPS

$4.47

Enterprise value

$149.25B

Business Summary

Sector: Healthcare
Industry: Diagnostics & Research
Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

Highlights

The net income has increased by 32% year-on-year
DHR's EPS is up by 29% year-on-year
The debt has surged by 152% year-on-year
The price to earnings (P/E) is 50% more than the 5-year quarterly average of 27.3 and 9% more than the last 4 quarters average of 37.6

Key stats

Shares outstanding
697.51M
Market cap
$127.64B
Enterprise value
$149.25B
EBIT
$4B
EBITDA
$5.16B
Price to earnings (P/E)
40.94
Price to book (P/B)
4.1
Price to sales (P/S)
7.34
EV/EBIT
37.28
EV/EBITDA
28.91
Net debt/EBITDA
4.18
EV/Sales
8.59
EBITDA margin
29.7%
Gross margin
55.9%
Net margin
18.8%
Operating margin
18.7%
Return on assets
5.2%
Return on equity
10.1%
Return on invested capital
17%
Return on capital employed
6.6%
Return on sales
23%
Debt to equity
0.84
Free cash flow
$3.47B
Free cash flow per share
$4.97
Book value per share
$44.6
Revenue per share
$24.92
TBVPS
$23.94
Current ratio
1.32
Quick ratio
0.92
Working capital
$2.68B
Dividend yield
0.38%
DPS
$0.7
Payout ratio
15.7%

DHR stock price

Financial performance

The net income has increased by 32% year-on-year
The net margin is up by 27% year-on-year
Danaher's operating income has increased by 6% YoY
The gross profit is up by 4.7% year-on-year

Valuation

Price to earnings (P/E)
Current price to earnings (P/E):
40.94
The price to earnings (P/E) is 50% more than the 5-year quarterly average of 27.3 and 9% more than the last 4 quarters average of 37.6
DHR's EPS is up by 29% year-on-year
Price to book (P/B)
Current price to book (P/B):
4.1
The P/B is 52% more than the 5-year quarterly average of 2.7 and 28% more than the last 4 quarters average of 3.2
The equity has contracted by 3.6% YoY
Price to sales (P/S)
Current price to sales (P/S):
7.34
DHR's P/S is 63% above its 5-year quarterly average of 4.5 and 24% above its last 4 quarters average of 5.9
Danaher's revenue has increased by 3.7% YoY

Efficiency

Danaher's ROE has increased by 23% YoY
The return on invested capital has declined by 18% year-on-year
DHR's return on sales is up by 14% year-on-year
DHR's ROA is up by 6% year-on-year

Dividends

DPS
$0.7
Dividend yield
0.38%
Payout ratio
15.7%

Recent dividends

Financial health

Assets vs liabilities
The total assets is 82% greater than the total liabilities
Debt vs equity
The debt is 16% smaller than the equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.